Energetics of the failing heart: New insights using genetic modification in the mouse

Archives des Maladies du Coeur et des Vaisseaux

Volumn 99, Issue 9, 2006, Pages 839-847

  Ingwall, J S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AMP specific 5 nucleotidase and AMP activated protein kinase; ATP synthesis pathways; Cardiac energetics; Creatine; Creatine phosphotransferase; PGC 1 ; PPAR

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; PURINE NUCLEOTIDE; 5' NUCLEOTIDASE; CREATINE KINASE; PURINE DERIVATIVE;

ARTICLE; DISEASE MODEL; DNA MODIFICATION; ENERGY TRANSFER; GENE CONTROL; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HEART FAILURE; HEART VENTRICLE REMODELING; MEDICAL LITERATURE; METABOLISM; NONHUMAN; PHENOTYPE; ANIMAL; CONGESTIVE HEART FAILURE; GENE EXPRESSION REGULATION; GENETICS; HEART CONTRACTION; HEART MUSCLE; MOUSE; REVIEW;

5'-NUCLEOTIDASE; ADENOSINE TRIPHOSPHATE; ANIMALS; CREATINE KINASE; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; MICE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PURINES;

EID: 33846846268     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004;95:568-78.
2. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005;115:547-55.
3. Ingwall JS. Transgenesis and cardiac energetics: new insights into cardiac metabolism. J Mol Cell Cardiol 2004;37:613-23.
4. Ingwall JS, Weiss RG. Is the falling heart energy starved? Circ Res 2004;95:135-45.
5. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-129.
6. Taegtmeyer H, Wilson CR, Razeghi P, Sharma S. Metabolic energetics and genetics in the neart. Ann N Y Acad Sci 2005;1047:208-18.
7. Tardiff JC. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005;10:237-48.
8. Ventura-Clapier RF, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004;555:1-15.
9. Young LH, Li J, Baron SJ, Russell RR. AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc Med 2005;15:110-8.
10. Shen W, Asai K, Uechi M, et al. Progressive loss of myocardial ATP due to a loss of total purines during, the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation 1999;100:2113-8.
11. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Failure Rev 2002;7:175-85.
12. Osorio JC, Stanley WC, Linke A, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002;106:606-12.
13. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78-90.
14. Arany Z, He H, Lin J, et al. Transcriptional coactivator PGC-1a controls the energy state and contractile function of cardiac muscle. Cell Metabolism 2005;1:259-71.
15. Ingwall JS, Kramer MF, Fifer MA, et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 1985;313:1050-4.
16. Nascimben L, Ingwall JS, Pauletto P, et al. Creatine kinase system in failing and nonfailinq human myocardium. Circulation 1996;9:1892-901.
17. Tian R, Nascimben L, Kaddurah-Daouk R, Ingwall JS. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol 1996;28:755-65.
18. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ Res 1996;78:893-902.
19. Nascimben L, Friedrich J, Liao R, Pauletto P, Pessina AC, Ingwall JS. Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation 1995;91:1824-33.
20. Ye Y, Wang C, Zhang J, et al. Myocardial creatine kinase kinetics and isoform expression in hearts with severe LV hypertrophy. Am J Physiol Heart Circ Physiol 2001;281:H376-86.
21. Zhang J, Bache RJ. The molecular energetics of the failing heart from animal models - large animal models. Heart Failure Rev 1999;4:255-67.
22. Tian R, Ingwall JS. Energetic basis for reduced contractile reserve in isolatearat hearts. Am J Physiol 1996;270:H1207-16.
23. Hamman BL, Bittl JA, Jacobus WE, Allen PD, Spencer RS, Tian R, et al. Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. Am J Physiol 1995;269:H1030-6.
24. Zweier JL, Jacobus WE, Korecky B, Brandejs-Barry Y. Bioenergetic consequences of cardiac phosphocreatine depletion induced by creatine analogue feeding. J Biol Chem 1991;266:20296-304.
25. Crozatier B, Badoual T, Boehm E, et al. Role of creatine kinase in cardiac excitation-contraction coupling: studies in creatine kinase-deficient mice. Faseb J 2002;16:653-60.
26. Nahrendorf M, Spindler M, Hu K, et al. Creatine kinase knockout mice show left ventricular hypertrophy and dilatation, but unaltered remodeling post-myocardial infarction. Cardiovasc Res 2005;65:419-27:
27. Nahrendorf M, Sfreif J, Hiller KH, et al. Multimodal, functional cardiac MR imaging in creatine kinase deficient mice reveals subtle abnormalities in myocardial perfusion and mechanics. Am J Physiol 2006 (in press).
28. Saupe KW, Spindler M, Tian R, Ingwall JS. Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. Circ Res 1998;82:898-907.
29. ten Hove M, Lygate CA, Fischer A, et al. Reduced inotropic reserve and increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-N-methyltransferase-knockout mice. Circulation 2005;111:2477-85.
30. Neubauer S, Remkes H, Spindler M, et al. Down regulation of the Na(+)-creatine co-transporter in failing human myocardium and in experimental heart failure. Circulation 1999;100:1847-50.
31. Wallis J, Lygate CA, Fischer A, et al. Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice. Circulation 2005;112:3131-9.
32. Bak MI, Ingwall JS. Acidosis during ischemia promotes adenosine triphosphate resynthesis in postischemic rat heart. In vivo regulation of 5′-nucleotidase. J Clin Invest 1994;93:40-9.
33. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997;246:259-73.
34. Chan AY, Dyck JR. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Can J Physiol Pharmacol 2005;83:24-8.
35. Xing Y, Musi N, Fujii N, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem 2003;278:28372-7.
36. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95.
37. Liao Y, Takashima S, Maeda N, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005;67:705-13.
38. Paulus W, Bronzwaer J. Myocardial contractile effects of nitric oxide. Heart Fail Rev 2002;7:371-83.
39. Ahmad F, Arad M, Musi N, et al. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 2005;112:3140-8.
40. Zou L, Shen M, Arad M, et al. N488I mutation of the gamma2-subunit results in bidirectional changes in AMP-activated protein kinase activity. Circ Res 2005;97:323-8.
41. Soltys CL, Kovacic S, Dyck JR. Activation of Cardiac AMP-activated Protein Kinase (AMPK) by LKB1 Expression or Chemical Hypoxia is Blunted by Increased Akt Activity. Am J Physiol Heart Circ Physiol 2006 (in press).
42. Sakamoto K, Zarrinpashneh E, Buds GR, et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPK [alpha] 2 but not AMPK[alpha]1. Am J Physiol Endocrinol Metab 2006;290:E780-8. Epub 2005.
43. Frederich M, Zhang L, Balschi JA. Hypoxia and AMP independently regulate AMP-activated protein kinase activity in heart. Am J Physiol Heart Circ Physiol 2005;288:H2412-21.
44. Tian R, Musi N, D'Agostmo J, Hirshman MF, Goodyear U. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001;104:1664-9.
45. Nascimben L, Ingwall J, Lorell B, et al. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 2004;44:662-7.
46. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004;279:32771-9.
47. St-Pierre J, Lin J, Krauss S, et al. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1 alpha and 1 beta (PGC-1 alpha and PGC-1 beta) in muscle cells. J Biol Chem 2003;278:26597-603.
48. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115-24.
49. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inaucible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-39.
50. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000;106:847-56.
51. Russell LK, Mansfield CM, Lehman JJ, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 2004;94:525-33.
52. Garnier A, Fortin D, Delomenle C, Momken I, Veksler V, Ventura-Clqpier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003;551 (Pt 2):491-501.
53. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-30.
54. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 2001;276:44390-5.
55. Campbell FM, Kozak R, Wagner A, et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002;277:4098-103.
56. Watanabe K, Fujii H, Takahashi T, et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 2000:275:22293-9.
57. Lopaschuk GD, Kozak R, Dyck JR, et al. The hearts of PPARa null mice exhibit reduced fatty acid oxidation rates and altered response to loading. Circulation 2000;102:11-8.
58. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005;112:2339-46.
59. Hansson A, Hance N, Dufour E, et al. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci U S A 2004;101:3136-41.
60. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-9.
61. van den Bosch BJ, van den Burg CM, Schoonderwoerd K, et al. Regional absence of mitochondria causing energy depletion in the myocardium of muscle LIM protein knockout mice. Cardiovasc Res 2005;65:411-8.
62. Ingwall JS. Energetic basis for heart failure-causes and consequences of decreased ATP and phosphocreatine. In: Mann D, editor. Heart Failure: A Companion to Braunwald's Heart Disease. Philadelphia: Sounders; 2004: 91-108.
63. Ingwall JS. ATP and the heart. Boston: Kluwer Academic Publishers;2002.